{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:24:26Z","timestamp":1791919466849,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gouty arthritis (GA) is a chronic systemic disease with recurrent acute monoarthritis. In a previous study, a higher incidence of acute flares was observed during the initial marked decrease in serum urate level. Our study evaluated the effect of early urate-lowering therapy in patients with acute GA flares.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included 40 patients with acute GA; of them, 20 received colchicine 0.5\u00a0mg colchicine twice daily, while 20 received probenecid 500\u00a0mg and colchicine 0.5\u00a0mg twice daily. We evaluated GA severity and laboratory data for 2 weeks after the initial therapy. Medians and interquartile ranges (IQRs) were calculated to evaluate clinical presentations between these two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Rapidly decreasing median serum uric acid levels was found in the patients treated with probenecid and colchicine compared with the patients treated with colchicine alone on day 8 (\u2212\u00a01.9 [IQR, \u2212\u00a03.7 to 0] vs 0.8 [IQR, \u2212\u00a00.1\u20132.2]; P\u2009&lt;\u20090.001). However, the median decrease in visual analog scale score did not differ significantly between the two groups (\u2212\u00a05.5 [IQR, \u2212\u00a08.0 to \u2212\u00a03.0] vs \u2212\u00a03.5 [IQR, \u2212\u00a05.9 to \u2212\u00a02.0]; P\u2009=\u20090.080).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>No significant increase was noted in acute gout flare severity or duration among GA patients treated with early aggressive control of hyperuricemia using probenecid plus colchicine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40001-022-00982-8","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T02:10:32Z","timestamp":1672971032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Early urate-lowering therapy in gouty arthritis with acute flares: a double-blind placebo controlled clinical trial"],"prefix":"10.1186","volume":"28","author":[{"given":"Deng-Ho","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Cheng-Chung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,6]]},"reference":[{"issue":"2","key":"982_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2020.105092","volume":"88","author":"V Kluck","year":"2021","unstructured":"Kluck V, Liu R, Joosten LAB. The role of interleukin-1 family members in hyperuricemia and gout. Joint Bone Spine. 2021;88(2): 105092.","journal-title":"Joint Bone Spine"},{"key":"982_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.637415","volume":"12","author":"QB Zhang","year":"2021","unstructured":"Zhang QB, Zhu D, Dai F, Huang YQ, Zheng JX, Tang YP, Dong ZR, Liao X, Qing YF. MicroRNA-223 suppresses IL-1beta and TNF-alpha production in gouty inflammation by targeting the NLRP3 inflammasome. Front Pharmacol. 2021;12: 637415.","journal-title":"Front Pharmacol"},{"key":"982_CR3","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3389\/fphar.2018.01123","volume":"9","author":"L Staurengo-Ferrari","year":"2018","unstructured":"Staurengo-Ferrari L, Ruiz-Miyazawa KW, Pinho-Ribeiro FA, Fattori V, Zaninelli TH, Badaro-Garcia S, Borghi SM, Carvalho TT, Alves-Filho JC, Cunha TM, et al. Trans-chalcone attenuates pain and inflammation in experimental acute gout arthritis in mice. Front Pharmacol. 2018;9:1123.","journal-title":"Front Pharmacol"},{"issue":"4","key":"982_CR4","first-page":"841","volume":"30","author":"CS Liu","year":"2003","unstructured":"Liu CS, Li TC, Lin CC. The epidemiology of hyperuricemia in children of Taiwan aborigines. J Rheumatol. 2003;30(4):841\u20135.","journal-title":"J Rheumatol"},{"key":"982_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13075-015-0610-9","volume":"17","author":"MJ Roughley","year":"2015","unstructured":"Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015;17:90.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"982_CR6","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.3899\/jrheum.141542","volume":"42","author":"JH Chen","year":"2015","unstructured":"Chen JH, Lan JL, Cheng CF, Liang WM, Lin HY, Tsay GJ, Yeh WT, Pan WH. Effect of urate-lowering therapy on the risk of cardiovascular disease and all-cause mortality in patients with gout: a case-matched cohort study. J Rheumatol. 2015;42(9):1694\u2013701.","journal-title":"J Rheumatol"},{"issue":"12","key":"982_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145193","volume":"10","author":"JH Chen","year":"2015","unstructured":"Chen JH, Lan JL, Cheng CF, Liang WM, Lin HY, Tsay GJ, Yeh WT, Pan WH. Effect of urate-lowering therapy on all-cause and cardiovascular mortality in hyperuricemic patients without gout: a case-matched cohort study. PLoS ONE. 2015;10(12): e0145193.","journal-title":"PLoS ONE"},{"key":"982_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010069.pub2","author":"MK Sriranganathan","year":"2014","unstructured":"Sriranganathan MK, Vinik O, Bombardier C, Edwards CJ. Interventions for tophi in gout. Cochrane Database Syst Rev. 2014. https:\/\/doi.org\/10.1002\/14651858.CD010069.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"22","key":"982_CR9","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1001\/jama.2015.1881","volume":"313","author":"CM van Durme","year":"2015","unstructured":"van Durme CM, Wechalekar MD, Landewe RB. Nonsteroidal anti-inflammatory drugs for treatment of acute gout. JAMA. 2015;313(22):2276\u20137.","journal-title":"JAMA"},{"issue":"10","key":"982_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186096","volume":"12","author":"A Abhishek","year":"2017","unstructured":"Abhishek A, Valdes AM, Jenkins W, Zhang W, Doherty M. Triggers of acute attacks of gout, does age of gout onset matter? A primary care based cross-sectional study. PLoS ONE. 2017;12(10): e0186096.","journal-title":"PLoS ONE"},{"issue":"6","key":"982_CR11","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/1756-185X.12648","volume":"18","author":"S Xu","year":"2015","unstructured":"Xu S, Liu X, Ming J, Chen S, Wang Y, Liu H, Peng Y, Wang J, Lin J, Ji H, et al. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia. Int J Rheum Dis. 2015;18(6):669\u201378.","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"982_CR12","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/art.1780200320","volume":"20","author":"SL Wallace","year":"1977","unstructured":"Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20(3):895\u2013900.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"982_CR13","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.semarthrit.2012.03.013","volume":"42","author":"RV Curiel","year":"2012","unstructured":"Curiel RV, Guzman NJ. Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review. Semin Arthritis Rheum. 2012;42(2):166\u201378.","journal-title":"Semin Arthritis Rheum"},{"key":"982_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006077.pub3","author":"R Seth","year":"2014","unstructured":"Seth R, Kydd AS, Buchbinder R, Bombardier C, Edwards CJ. Allopurinol for chronic gout. Cochrane Database Syst Rev. 2014. https:\/\/doi.org\/10.1002\/14651858.CD006077.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"982_CR15","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/bjp.2008.20","volume":"153","author":"EW Chia","year":"2008","unstructured":"Chia EW, Grainger R, Harper JL. Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: a rationale for use of low-dose colchicine. Br J Pharmacol. 2008;153(6):1288\u201395.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"982_CR16","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s11926-008-0036-3","volume":"10","author":"G Nuki","year":"2008","unstructured":"Nuki G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep. 2008;10(3):218\u201327.","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"982_CR17","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3899\/jrheum.121301","volume":"40","author":"K Pui","year":"2013","unstructured":"Pui K, Gow PJ, Dalbeth N. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. J Rheumatol. 2013;40(6):872\u20136.","journal-title":"J Rheumatol"},{"key":"982_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3899\/jrheum.140460","volume":"92","author":"AS Kydd","year":"2014","unstructured":"Kydd AS, Seth R, Buchbinder R, Falzon L, Edwards CJ, van der Heijde DM, Bombardier C. Urate-lowering therapy for the management of gout: a summary of 2 Cochrane reviews. J Rheumatol Suppl. 2014;92:33\u201341.","journal-title":"J Rheumatol Suppl"},{"key":"982_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010457.pub2","author":"AS Kydd","year":"2014","unstructured":"Kydd AS, Seth R, Buchbinder R, Edwards CJ, Bombardier C. Uricosuric medications for chronic gout. Cochrane Database Syst Rev. 2014. https:\/\/doi.org\/10.1002\/14651858.CD010457.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"982_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/BOR.0000000000000154","volume":"27","author":"PP Khanna","year":"2015","unstructured":"Khanna PP, FitzGerald J. Evolution of management of gout: a comparison of recent guidelines. Curr Opin Rheumatol. 2015;27(2):139\u201346.","journal-title":"Curr Opin Rheumatol"},{"issue":"12","key":"982_CR21","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00296-016-3579-z","volume":"36","author":"F Eminaga","year":"2016","unstructured":"Eminaga F, La-Crette J, Jones A, Abhishek A. Does the initiation of urate-lowering treatment during an acute gout attack prolong the current episode and precipitate recurrent attacks: a systematic literature review. Rheumatol Int. 2016;36(12):1747\u201352.","journal-title":"Rheumatol Int"},{"issue":"9","key":"982_CR22","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00702-009-0253-6","volume":"116","author":"E Vamos","year":"2009","unstructured":"Vamos E, Voros K, Zadori D, Vecsei L, Klivenyi P. Neuroprotective effects of probenecid in a transgenic animal model of Huntington\u2019s disease. J Neural Transm. 2009;116(9):1079\u201386.","journal-title":"J Neural Transm"},{"issue":"5","key":"982_CR23","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S1734-1140(11)70633-8","volume":"63","author":"JB Park","year":"2011","unstructured":"Park JB, Kim SJ. Anti-hypertensive effects of probenecid via inhibition of the alpha-adrenergic receptor. Pharmacol Rep. 2011;63(5):1145\u201350.","journal-title":"Pharmacol Rep"},{"key":"982_CR24","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.neuroscience.2015.05.070","volume":"301","author":"R Wei","year":"2015","unstructured":"Wei R, Wang J, Xu Y, Yin B, He F, Du Y, Peng G, Luo B. Probenecid protects against cerebral ischemia\/reperfusion injury by inhibiting lysosomal and inflammatory damage in rats. Neuroscience. 2015;301:168\u201377.","journal-title":"Neuroscience"},{"issue":"3","key":"982_CR25","doi-asserted-by":"publisher","first-page":"C761","DOI":"10.1152\/ajpcell.00227.2008","volume":"295","author":"W Silverman","year":"2008","unstructured":"Silverman W, Locovei S, Dahl G. Probenecid, a gout remedy, inhibits pannexin 1 channels. Am J Physiol Cell Physiol. 2008;295(3):C761-767.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"10","key":"982_CR26","doi-asserted-by":"publisher","first-page":"C1034","DOI":"10.1152\/ajpcell.00175.2012","volume":"303","author":"F Xiao","year":"2012","unstructured":"Xiao F, Waldrop SL, Khimji AK, Kilic G. Pannexin1 contributes to pathophysiological ATP release in lipoapoptosis induced by saturated free fatty acids in liver cells. Am J Physiol Cell Physiol. 2012;303(10):C1034-1044.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"5","key":"982_CR27","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.jhep.2015.06.013","volume":"63","author":"A Iracheta-Vellve","year":"2015","unstructured":"Iracheta-Vellve A, Petrasek J, Satishchandran A, Gyongyosi B, Saha B, Kodys K, Fitzgerald KA, Kurt-Jones EA, Szabo G. Inhibition of sterile danger signals, uric acid and ATP, prevents inflammasome activation and protects from alcoholic steatohepatitis in mice. J Hepatol. 2015;63(5):1147\u201355.","journal-title":"J Hepatol"},{"issue":"8","key":"982_CR28","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s10067-019-04566-6","volume":"38","author":"CA Janssen","year":"2019","unstructured":"Janssen CA, Oude Voshaar MAH, Ten Klooster PM, Vonkeman HE, van de Laar M. Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare. Clin Rheumatol. 2019;38(8):2233\u20139.","journal-title":"Clin Rheumatol"},{"issue":"11","key":"982_CR29","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/rheumatology\/keu157","volume":"53","author":"A Latourte","year":"2014","unstructured":"Latourte A, Bardin T, Richette P. Prophylaxis for acute gout flares after initiation of urate-lowering therapy. Rheumatology. 2014;53(11):1920\u20136.","journal-title":"Rheumatology"},{"issue":"4","key":"982_CR30","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3109\/15360288.2010.526174","volume":"24","author":"DM Peterson","year":"2010","unstructured":"Peterson DM. Nonsteroidal anti-inflammatory drugs and colchicine to prevent gout flare during early urate-lowering therapy: perspectives on alternative therapies and costs. J Pain Palliat Care Pharmacother. 2010;24(4):402\u20134.","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"6","key":"982_CR31","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jbspin.2020.09.014","volume":"87","author":"E Ebstein","year":"2020","unstructured":"Ebstein E, Forien M, Norkuviene E, Richette P, Mouterde G, Daien C, Ea HK, Briere C, Liote F, Petraitis M, et al. UltraSound evaluation in follow-up of urate-lowering therapy in gout phase 2 (USEFUL-2): duration of flare prophylaxis. Joint Bone Spine. 2020;87(6):647\u201351.","journal-title":"Joint Bone Spine"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-022-00982-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-022-00982-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-022-00982-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T11:00:03Z","timestamp":1673348403000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-022-00982-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,6]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["982"],"URL":"https:\/\/doi.org\/10.1186\/s40001-022-00982-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1914012\/v1","asserted-by":"object"}]},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,6]]},"assertion":[{"value":"31 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. This study was approved by the Institutional Review Board of the Tri-Service General Hospital (TSGHIRB No. 1-104-05-001).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors agree with the publication of this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no conflict of interest regarding the publication of this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}